This week, FDA finally published a December 2012 warning letter on its website, showcasing its
first-ever enforcement action based on a company's social media
activity. In the letter, FDA interprets a dietary supplement
company "liking" a consumer testimonial posted to its
Facebook website as an implied endorsement of the underlying claim
content.
The offending post, FDA observed, made an impermissible drug
claim by implying that the company's product was intended for
use in the diagnosis, cure, mitigation, treatment or prevention of
a disease when it stated,"[Product] has done wonders for
me. I take it intravenously 2x a week and it has helped me
tremendously. It enabled me to keep cancer at bay without the
use of chemo and radiation...Thank you [Company]." While
the controversial post has since been removed, FDA's
interpretation that a "Like" implies endorsement could be
a precedent-setting action. Re-tweeters beware!